Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Collins

Showing results (11-20 of 103) with videos related to

Pageof 11
Sort By:
Future Medicinal Chemistry|March 16, 2016
Recent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapyStephanie M Myers, Ian Collins
Journal of Chemical Biology|July 2, 2009
Measuring and interpreting the selectivity of protein kinase inhibitorsLynette A Smyth, Ian Collins
Molecules (Basel, Switzerland)|October 29, 2014
Diversity-oriented synthetic strategies applied to cancer chemical biology and drug discoveryIan Collins, Alan M Jones
Drug Discovery Today. Technologies|June 16, 2019
A critical evaluation of the approaches to targeted protein degradation for drug discoveryRajesh Chopra, Amine Sadok, Ian Collins
Current Topics in Medicinal Chemistry|November 26, 2009
Fragment-based discovery of inhibitors of protein kinase BThomas G Davies, Steven J Woodhead, Ian Collins
Expert Opinion on Drug Discovery|April 19, 2013
Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapiesThomas P Matthews, Alan M Jones, Ian Collins
Bioorganic & Medicinal Chemistry|May 4, 2011
Design and evaluation of 3-aminopyrazolopyridinone kinase inhibitors inspired by the natural product indirubinLynette A Smyth, Thomas P Matthews, Ian Collins
Methods in Molecular Biology (Clifton, N.J.)|July 12, 2017
Identifying and Validating Tankyrase Binders and Substrates: A Candidate ApproachKatie Pollock, Michael Ranes, Ian Collins, et al.
Nature Reviews. Cancer|November 16, 2007
CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?Laurent Antoni, Nayanta Sodha, Ian Collins, et al.
The Biochemical Journal|March 17, 2017
Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathwayIan Collins, Hannah Wang, John J Caldwell, et al.
Pageof 11

Showing results (11-20 of 103) with videos related to

Sort By:
Pageof 11
Future Medicinal Chemistry|March 16, 2016
Recent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapyStephanie M Myers, Ian Collins
Journal of Chemical Biology|July 2, 2009
Measuring and interpreting the selectivity of protein kinase inhibitorsLynette A Smyth, Ian Collins
Molecules (Basel, Switzerland)|October 29, 2014
Diversity-oriented synthetic strategies applied to cancer chemical biology and drug discoveryIan Collins, Alan M Jones
Drug Discovery Today. Technologies|June 16, 2019
A critical evaluation of the approaches to targeted protein degradation for drug discoveryRajesh Chopra, Amine Sadok, Ian Collins
Current Topics in Medicinal Chemistry|November 26, 2009
Fragment-based discovery of inhibitors of protein kinase BThomas G Davies, Steven J Woodhead, Ian Collins
Expert Opinion on Drug Discovery|April 19, 2013
Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapiesThomas P Matthews, Alan M Jones, Ian Collins
Bioorganic & Medicinal Chemistry|May 4, 2011
Design and evaluation of 3-aminopyrazolopyridinone kinase inhibitors inspired by the natural product indirubinLynette A Smyth, Thomas P Matthews, Ian Collins
Methods in Molecular Biology (Clifton, N.J.)|July 12, 2017
Identifying and Validating Tankyrase Binders and Substrates: A Candidate ApproachKatie Pollock, Michael Ranes, Ian Collins, et al.
Nature Reviews. Cancer|November 16, 2007
CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?Laurent Antoni, Nayanta Sodha, Ian Collins, et al.
The Biochemical Journal|March 17, 2017
Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathwayIan Collins, Hannah Wang, John J Caldwell, et al.
Pageof 11